LAS VEGAS, Aug. 21, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy.
